Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
MALVERN, Pa., June 29, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet …